Former Dexcom Scientist to Lead Intellectual Property Work
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190416005303/en/
Dr. Tapsak most recently has been Professor of Chemistry and Biochemistry and Interim Assistant Vice President and Dean of Graduate Studies and Sponsored Research at Bloomsburg University of Pennsylvania.
In addition to Dr. Tapsak’s focus on intellectual property at Know Labs he will work to support the product development, manufacturing and launch of the Company’s UBAND Calorie Counter wearable and help drive toward FDA approval of the Company’s non-invasive UBAND Continuous Glucose Monitor.
Prior to his academic assignment Tapsak began his work with medical devices with Medtronic, and then with Dexcom. At Dexcom, a multi-billion dollar provider of continuous glucose monitoring (CGM) systems, Dr. Tapsak was the 12th employee. He was involved with inventions that are broad in scope and range from:
- Composition of matter, manufacturing techniques for key Dexcom membrane technology
- Dexcom sensor design and geometry
- Electrochemical performance of Dexcom sensor
- Dexcom system design and function
- Dexcom biointerface design and composition of matter
As a result of Dr. Tapsak’s work, he currently holds 65 issued United States patents, 52 of which are Dexcom assigned patents.
Phil Bosua, Know Labs CEO, stated, “We are thrilled to have Mark Tapsak join the Know Labs team. He is a pioneer in the continuous glucose monitoring marketplace, he understands our technology and will play a key role to reinforcing the value of our intellectual property and our go to market strategy.”
Upon joining Know Labs, Tapsak said, “When I first visited the Know Labs research facility in Seattle last year I was stunned with the capacity of the technology. I assisted with some testing which verified its fundamental elements. I am excited to be a part of the team to bring the technology to market. It is a broad platform that will have a significant impact on human health diagnostics. Continuous glucose monitoring is a special interest of mine. Know Labs UBAND will perform that function accurately and most important, truly non-invasively.”
Neither Dr. Tapsak nor Know Labs, Inc. is affiliated with Dexcom, Inc.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNWN.” The company’s technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. For more information on Know Labs, visit the company’s website at www.knowlabs.co
Safe Harbor Statement
This video at the link above and this release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words may, would, will, expect, estimate, can, believe, potential and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors.